A Double-Blind, Randomized, Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
A Double-Blind, Randomized, Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
To evaluate safety and efficacy of two adalimumab dosing regimens for induction and maintenance (standard and higher dosing) in achieving clinical remission in subjects with moderately to severely active ulcerative colitis.
Inclusion Criteria:
Exclusion Criteria:
Chicago, Illinois 60611-2927, United States
Milwaukee, Wisconsin 53226-3522, United States
Vandœuvre-lès-Nancy, Meurthe-et-Moselle 54511, France
Kiel, Schleswig-Holstein 24105, Germany
Pécs, Pecs 7624, Hungary
Petakh Tikva, Tel Aviv 4941492, Israel
Sakura-shi, Chiba 285-8741, Japan
Kurume-shi, Fukuoka 830-0011, Japan
Nishinomiya-shi, Hyōgo 663-8501, Japan
Sagamihara-shi, Kanagawa 252-0375, Japan
Susaki-shi, Kochi 785-8501, Japan
Takatsuki-shi, Osaka 569-8686, Japan
Kawagoe-shi, Saitama 350-8550, Japan
Bunkyo-ku, Tokyo 113-8519, Japan
Minato-ku, Tokyo 108-8642, Japan
Mitaka-shi, Tokyo 181-8611, Japan
Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-168, Poland
Kharkiv, Kharkiv Oblast 61039, Ukraine
Kherson, 73000, Ukraine
Oxford, OX3 9DU, United Kingdom